Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib and MO-03 in mRCC After Progression to Immunotherapy
NCT07578025Phase 2Not yet recruiting
- Sponsor
- City of Hope
- Start
- Nov 2026
- Primary completion
- Jun 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib, clostridium butyricum in renal cell carcinoma (RCC), sponsored by City of Hope. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
zanzalintinibclostridium butyricum
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07578025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578025.